Both outcomes are clinically meaningful, but they illustrate why BMI at treatment initiation shapes expectations about results
Tamborlane WV, Barrientos-Perez M, Fainberg U, et al
How they did it The study group searched Google and Bing to find websites advertising semaglutide without a prescription
Cng dng Bt tng da, ci thin ln da xn mu ch sau 7 ngy (*) Lm m nm, tn nhang, vt thm, i mi mt cch hiu qu, cho ln da u mu rng r Cng thc vt tri kt hp 2 hot cht lm trng Glutathione 700mg v Niacinamide mang n iu bt ng khi chm sc da mi ngy c ch melamin, nui dng da sng mn, ti tn Cung cp m t nhin, duy tr ln da mm mi, mn mng, nga kh da Se kht l chn lng, gim nhn, gim nguy c mn Phc hi da b tn thng do UV, v thc y ti to da mi ti sng
Real-world dosing and outcomes 6-month persister loss about 12-13% (Hankosky DOM 2025), broad-cohort about -9.8% (Adamidis Cureus 2026), telehealth completers near -23% (Duncan Obesity Pillars 2026)
They also face an increased risk of serious and potentially life-threatening health problems